Literature DB >> 18026926

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.

D M Nathan1, J B Buse, M B Davidson, E Ferrannini, R R Holman, R Sherwin, B Zinman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18026926     DOI： 10.1007/s00125-007-0873-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  14 in total

1.  Rosiglitazone--continued uncertainty about safety.

Authors:  Jeffrey M Drazen; Stephen Morrissey; Gregory D Curfman
Journal:  N Engl J Med       Date:  2007-06-05       Impact factor: 91.245

2.  The record on rosiglitazone and the risk of myocardial infarction.

Authors:  Bruce M Psaty; Curt D Furberg
Journal:  N Engl J Med       Date:  2007-06-05       Impact factor: 91.245

3.  Rosiglitazone and cardiotoxicity--weighing the evidence.

Authors:  David M Nathan
Journal:  N Engl J Med       Date:  2007-06-05       Impact factor: 91.245

4.  Rosiglitazone and cardiovascular risk.

Authors:  Bruce M Psaty; Curt D Furberg
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

5.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; Curt D Furberg
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

6.  Thiazolidinedione use and bone loss in older diabetic adults.

Authors:  Ann V Schwartz; Deborah E Sellmeyer; Eric Vittinghoff; Lisa Palermo; Beata Lecka-Czernik; Kenneth R Feingold; Elsa S Strotmeyer; Helaine E Resnick; Laura Carbone; Brock A Beamer; Seok Won Park; Nancy E Lane; Tamara B Harris; Steven R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2006-04-11       Impact factor: 5.958

7.  Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Ramón Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  N Engl J Med       Date:  2007-06-05       Impact factor: 91.245

8.  Thiazolidinediones and heart failure: a teleo-analysis.

Authors:  Sonal Singh; Yoon K Loke; Curt D Furberg
Journal:  Diabetes Care       Date:  2007-05-29       Impact factor: 19.112

Review 9.  Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

Authors:  Rodrigo M Lago; Premranjan P Singh; Richard W Nesto
Journal:  Lancet       Date:  2007-09-29       Impact factor: 79.321

10.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

Authors:  A Michael Lincoff; Kathy Wolski; Stephen J Nicholls; Steven E Nissen
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272
View more
  29 in total

1.  Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

Authors:  Rikje Ruiter; Loes E Visser; Myrthe P P van Herk-Sukel; Petronella H Geelhoed-Duijvestijn; Sandra de Bie; Sabine M J M Straus; Peter G M Mol; Silvana A Romio; Ron M C Herings; Bruno H Ch Stricker
Journal:  Drug Saf       Date:  2012-06-01       Impact factor: 5.606

2.  Short-term impact of HbA1c on morbidity and all-cause mortality in people with type 2 diabetes: a Danish population-based observational study.

Authors:  M V Skriver; H Støvring; J K Kristensen; M Charles; A Sandbæk
Journal:  Diabetologia       Date:  2012-06-27       Impact factor: 10.122

3.  Safety of very tight blood glucose control in type 2 diabetes.

Authors:  Philip Home
Journal:  BMJ       Date:  2008-03-01

4.  Rosiglitazone: to be or not to be?

Authors:  A J Scheen
Journal:  Diabetologia       Date:  2009-04-18       Impact factor: 10.122

Review 5.  Alternative Medicine in Diabetes - Role of Angiogenesis, Oxidative Stress, and Chronic Inflammation.

Authors:  Mohamed F El-Refaei; Suha H Abduljawad; Ahmed H Alghamdi
Journal:  Rev Diabet Stud       Date:  2015-02-10

6.  Metformin suppresses hepatic gluconeogenesis and lowers fasting blood glucose levels through reactive nitrogen species in mice.

Authors:  Y Fujita; M Hosokawa; S Fujimoto; E Mukai; A Abudukadier; A Obara; M Ogura; Y Nakamura; K Toyoda; K Nagashima; Y Seino; N Inagaki
Journal:  Diabetologia       Date:  2010-03-29       Impact factor: 10.122

Review 7.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

8.  Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.

Authors:  Ingrid Leal; Silvana A Romio; Martijn Schuemie; Alessandro Oteri; Miriam Sturkenboom; Gianluca Trifirò
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

9.  Thiazolidinediones and cardiovascular risk - a question of balance.

Authors:  Erland Erdmann; Bernard Charbonnel; Robert Wilcox
Journal:  Curr Cardiol Rev       Date:  2009-08

10.  The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.

Authors:  Ralph A DeFronzo; Miguel N Hissa; Alan J Garber; Jorge Luiz Gross; Raina Yuyan Duan; Shoba Ravichandran; Roland S Chen
Journal:  Diabetes Care       Date:  2009-05-28       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.